Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 oct. 2023 16h27 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
06 sept. 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 sept. 2023 16h37 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
09 août 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
Azenosertib monotherapy achieved an ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients who received intermittent dosing Identified azenosertib monotherapy RP2D,...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 août 2023 16h28 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
01 août 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
15 juin 2023 06h01 HE
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
06 juin 2023 06h00 HE
|
ZENTALIS PHARMACEUTICALS
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D...
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
25 mai 2023 17h38 HE
|
ZENTALIS PHARMACEUTICALS
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7%...
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
23 mai 2023 07h00 HE
|
ZENTALIS PHARMACEUTICALS
Overview of data to be presented at the 2023 ASCO Annual Meeting to be included in the update Live webcast to be held on Tuesday, June 6th at 8:00 a.m. ET NEW YORK and SAN DIEGO, May 23, 2023 ...